Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma

• Published in: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Vol. 21; no. 7; pp. 1371 - 1377
• Main Authors: Holmberg, Marcus, Ghorbani, Poya, Gilg, Stefan, Del Chiaro, Marco, Arnelo, Urban, Löhr, J.-Matthias, Sparrelid, Ernesto
• Format: Journal Article
• Language: English
• Published: Switzerland Elsevier B.V 01.10.2021; Elsevier Limited
• Subjects: Adenocarcinoma; Adenocarcinoma, Mucinous - surgery; Cancer; Carcinoma, Pancreatic Ductal - surgery; Chemotherapy; Classification; Death; Humans; Intraductal papillary mucinous neoplasm; Invasive; Invasiveness; Medicin och hälsovetenskap; Pancreas; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Pancreatic Intraductal Neoplasms - surgery; Pancreatic Neoplasms; Pancreatic Neoplasms - surgery; Patients; Regression analysis; Survival; Tumors; Variables; Intraductal papillary mucinous neoplasm; Survival; Pancreatic ductal adenocarcinoma; Invasive
• ISSN: 1424-3903; 1424-3911; 1424-3911
• DOI: 10.1016/j.pan.2021.07.009

Resections for intraductal papillary mucinous neoplasm (IPMN) have increased last decades. Overall survival (OS) for conventional pancreatic ductal adenocarcinoma (PDAC) is well known but OS for invasive IPMN (inv-IPMN) is not as conclusive. This study aims to elucidate potential differences in clinicopathology and OS between these tumor types and to investigate if the raised number of resections have affected outcome. Consecutive patients ≥18 years of age resected for inv-IPMN and PDAC at Karolinska University Hospital between 2009 and 2018 were included. Clinicopathological variables were analyzed in multivariable regression models. Outcome was assessed calculating two-year OS, estimating OS using the Kaplan-Meier model and comparing survival functions with log-rank test. 513 patients were included, 122 with inv-IPMN and 391 with PDAC. During the study period both the proportion resected inv-IPMN and two-year OS, irrespective of tumor type, increased (2.5%–45%; p < 0.001 and 44%–57%; p = 0.005 respectively). In Kaplan-Meier survival analysis inv-IPMN had more favorable median OS (mOS) compared to PDAC (33.6 months vs 19.3 months, p = 0.001). However, in multivariable Cox Regression analysis, tumor type was not a predictor for death, but so were resection period, tumor subtype and N-stage (all p < 0.001). In this large single center observational cohort study, inv-IPMN seemed to have favorable survival outcome compared to PDAC, but after adjusting for predictors for death this benefit vanished. The combination of a pronounced increase in resected inv-IPMN and a concurrent hazard abatement for death within 2 years during the study period proved to be a principal factor.